Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arzoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 0.96 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | PLD2 | O14939 | 1/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | C5 | P01031 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arzoxifene SCHEMBL29354336 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL285277 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL5970803 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL29351083 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL699600 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Arzoxifene SCHEMBL5493113 | 0.96 | ESR1 (0.96) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7450925 | 0.93 | ESR1 (0.89) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL3743164 | 0.93 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7460587 | 0.92 | ESR1 (0.88) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL3807019 | 0.92 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103006570-B | Arzoxifene immediate-release pellets and preparation method thereof | SUN WEIHUI | 2013-12-25 | — | — | CN | disclosed |
| CN-103006570-A | Arzoxifene immediate-release pellets and preparation method thereof | LI ZHENGMEI | 2013-04-03 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PTGES2, PTGS2, PTGER2 | ESR1 2693/4885ESR2 291/4885MEN1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.